Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Xilio Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- +1 vs. Q2 2025
- Shares held
- 22.1M
- −1.74M (−7.3%) vs. Q2 2025
- Total value
- $18.6M
- +$2.43M (+15.0%) vs. Q2 2025
- New holders
- 4
- 6 more added
- Sold out
- 3
- 4 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 246 | $207 | 0.00% | −85−25.7% | Reduced |
| Citigroup Inc | 258 | $217 | 0.00% | +258 | New |
| Private Wealth Management Group, LLC | 310 | $262 | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 830 | $691 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,037 | $1.72K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 3,300 | $2.78K | 0.00% | 00.0% | Unchanged |
| Investors Asset Management of Georgia Inc | 10,000 | $8.43K | 0.00% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $8.43K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $8.66K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 13,652 | $11.5K | 0.00% | −226,317−94.3% | Reduced |
| Raymond James Financial Inc | 18,761 | $15.8K | 0.00% | 00.0% | Unchanged |
| SevenBridge Financial Group, LLC | 25,000 | $19.3K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 24,736 | $20.0K | 0.00% | +24,736 | New |
| Mariner, LLC | 25,000 | $21.1K | 0.00% | 00.0% | Unchanged |
| Aptus Capital Advisors, LLC | 25,000 | $21.1K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 29,689 | $25.0K | 0.00% | +29,689 | New |
| LPL Financial LLC | 31,000 | $26.1K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 32,130 | $27.1K | 0.00% | +32,130 | New |
| Bridgeway Capital Management, LLC | 56,081 | $47.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 66,609 | $56.1K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 76,045 | $64.1K | 0.00% | +41,324+119.0% | Added |
| Two Sigma Investments, LP | 87,790 | $74.0K | 0.00% | +9,758+12.5% | Added |
| State Street Corp | 163,890 | $138.1K | 0.00% | +120,500+277.7% | Added |
| Balyasny Asset Management LLC | 198,859 | $167.6K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 204,700 | $172.5K | 0.00% | +40,500+24.7% | Added |
| Trustees of Columbia University in the City of New York | 249,635 | $210.4K | 0.03% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 328,794 | $277.1K | 0.00% | +93,338+39.6% | Added |
| Geode Capital Management, LLC | 328,972 | $277.3K | 0.00% | −40,688−11.0% | Reduced |
| FMR LLC | 511,820 | $431.3K | 0.00% | 00.0% | Unchanged |
| AJU IB Investment Co., Ltd. | 667,742 | $595.6K | 0.52% | 00.0% | Unchanged |
| Morgan Stanley | 961,917 | $810.6K | 0.00% | −482,409−33.4% | Reduced |
| Vanguard Group Inc | 1,255,692 | $1.06M | 0.00% | +104,669+9.1% | Added |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.24M | 7.59% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,483,758 | $1.25M | 0.55% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $3.85M | 0.26% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 9,105,451 | $7.67M | 0.43% | 00.0% | Unchanged |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −1,333,000−100.0% | Sold out |
| Avantax Planning Partners, Inc. | 0 | $0 | 0.00% | −142,338−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −15,412−100.0% | Sold out |